Letrozole, marketed under the pharmaceutical brand name Femara, is a third generation non steroidal aromatase inhibitor with FDA approval for breast cancer treatment, sharing its non steroidal competitive reversible mechanism with Anastrozole while delivering a substantially more potent aromatase suppression profile that has generated extensive comparative AI research between the two compounds. This formulation delivers 2.5mg per tablet in a 30 count format, consistent with the concentration most commonly referenced in aromatase inhibition and estrogen biosynthesis research literature.

Letrozole and Anastrozole share the same non steroidal triazole based mechanism of CYP19A1 competitive reversible inhibition; both binding the aromatase enzyme’s active site and blocking androgen to estrogen conversion without permanently inactivating the enzyme. The meaningful research distinction between the two lies in potency. Letrozole produces documented aromatase suppression of approximately 98 to 99% in clinical studies compared to Anastrozole’s approximately 96 to 97% suppression, a difference that while modest in absolute terms has generated specific comparative research into whether near complete versus complete aromatase suppression produces distinguishable downstream effects on estrogen dependent biological endpoints. This potency difference makes Letrozole the more aggressive non steroidal AI option in CSD’s range and positions it as the reference compound for maximum non steroidal aromatase suppression research alongside Exemestane’s irreversible steroidal inactivation mechanism.

CSD’s aromatase inhibitor range now covers all three mechanistically distinct AI approaches: Anastrozole’s reversible non steroidal competitive inhibition at standard suppression potency, Letrozole’s reversible non steroidal competitive inhibition at near maximal suppression potency, and Exemestane’s irreversible steroidal mechanism based inactivation with androgenic metabolite activity. Researchers examining the relationship between AI mechanism type, suppression depth, and downstream biological effects can source all three compounds from a single verified Canadian supplier for comprehensive comparative aromatase inhibition research coverage.

Every batch of CSD’s Letrozole is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our estrogen management range covering Letrozole, Anastrozole, Exemestane, and the full SERM family represents the most comprehensive hormonal regulation research sourcing available from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store in a cool, dry place away from direct light and heat. Intended for research purposes only.

Commonly researched alongside Anastrozole and Exemestane in comparative aromatase inhibitor potency and estrogen suppression studies. Browse CSD’s full PCT and hormone research range for complete sourcing.